This technology provides a pharmaceutical composition for the prevention and treatment of diabetes, as well as a health functional food for diabetes management, using linalyl acetate—a fragrance component derived from sources such as Eucalyptus globulus—as an active ingredient. It can be formulated with anethole, another plant-derived component, as needed.
Diabetes is a condition characterized by chronic hyperglycemia due to insulin deficiency or resistance, leading to metabolic complications such as dyslipidemia, oxidative stress, and atherosclerosis. Some GLP-1 class anti-diabetic drugs have raised concerns regarding side effects, including risks of pancreatitis and pancreatic cancer with long-term use. While linalyl acetate and anethole have been reported to have anti-inflammatory and anti-allergic effects, their link to diabetes treatment was previously unknown, limiting their use as natural anti-diabetic agents.
This technology is designed to increase the expression or activity of AMP-activated protein kinase (AMPK), thereby regulating lipid metabolism and enhancing cellular glucose uptake. The composition, including its combination with anethole, is covered under the scope of the patent. It can also be formulated with existing anti-diabetic compounds such as metformin, sulfonylureas, thiazolidinediones, and acarbose. Applicable to the development of type 2 diabetes combination drugs, blood glucose management supplements, and as an adjunct therapy for oral hypoglycemic agents, this technology repurposes plant essential oil components into blood glucose regulators, potentially reducing reliance on synthetic drugs.
This invention was developed with support from the Ministry of Science, ICT and Future Planning for research on the inhibitory effects of aroma on ischemic brain injury and changes in synaptic plasticity.
N/A
